IMPORTANT: Read the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.
About FOXO4-DRI
FOXO4-DRI (FOXO4 D-Retro-Inverso) is a synthetic senolytic peptide designed to disrupt the interaction between the FOXO4 protein and p53 within senescent (“zombie”) cells. By blocking this interaction, p53 is freed to trigger apoptosis selectively in senescent cells while sparing healthy ones. In preclinical research, clearing senescent cells with FOXO4-DRI restored fitness, fur density, and kidney function in aged mice, making it one of the most-discussed compounds in longevity-focused peptide research.
Dosing & Reconstitution Guide
— Reconstitution & Protocol —
Reconstitute: Mix the vial with 3.0 mL (300 units) of bacteriostatic (BAC) water. Administration: Subcutaneous injection. Timing: May dose any time of day or night, but establish a consistent dosing time. Special storage/handling requirements: None beyond standard peptide handling. Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.
Schedule: Once daily, 7 days per week.
Cycle Length: 8–16 week cycle followed by a 4–8 week washout period.
Goal: Senolytic support — selective clearance of senescent cells based on preclinical evidence.
Frequency: Inject once daily subcutaneously.
Phase
Dose
Syringe (U-100)
Weeks 1–4
250 mcg once daily
8 units (0.08 mL)
Weeks 5–8
375 mcg once daily
11 units (0.11 mL)
Weeks 9–16
500 mcg once daily
15 units (0.15 mL)
Benefits
Senolytic Activity – Selectively induces apoptosis in senescent cells by disrupting the FOXO4–p53 interaction (preclinical).
Tissue Homeostasis – In aged and chemotherapy-treated mice, senescent-cell clearance restored tissue homeostasis and organ function.
Longevity Research – Studied as a candidate geroprotector for counteracting cellular aging processes.
Research Sources
Citations for verification. Many studies are animal/in-vitro.
Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132-147.e16.PMID: 28340339
Human clinical data for FOXO4-DRI are not available; current evidence is limited to animal and in-vitro senolytic studies.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
